阿尔茨海默病中的代谢失调:一种大脑代谢学方法
Anke Hüls1,2,3,4, Youran Tan2, Emma Casey1
1Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, Georgia, USA.
Alzheimer's & dementia : the journal of the Alzheimer's Association
|September 11, 2025
概括
这项研究确定了155种代谢特征和36种与阿尔茨海默病 (AD) 神经病理学相关的途径,揭示了葡萄糖和腺代谢的关键变化,特别是在非APOE ε4载体中.
科学领域:
- 神经科学是一个神经科学.
- 代谢学 代谢学 代谢学
- 生物化学 生化学
背景情况:
- 阿尔茨海默氏症 (AD) 神经病理学涉及复杂的生物途径和分子.
- 了解这些分子基础对于开发有效的诊断和治疗方法至关重要.
研究的目的:
- 确定与阿尔茨海默病 (AD) 神经病理学相关的特定生物途径和分子.
- 研究代谢失调和遗传因素在阿尔茨海默病中的作用.
主要方法:
- 在162个人类前额皮质样本上进行了高分辨率的代谢学分析.
- 样本来源于埃莫里阿尔茨海默氏症疾病研究中心 (ADRC) 的大脑银行.
- 综合的神经病理评估与代谢分析一起进行.
主要成果:
- 155种独特的代谢特征和36种途径与AD神经病理标志物有关.
- 18种新代谢物,包括葡萄糖和氨酸5'-二二,被证实具有1级证据.
- 遗传变异性,特别是阿波利波蛋白E (APOE) ε4等位基因,影响了代谢关联,非载体的显著差异.
结论:
- 大脑组织的高分辨率代谢分析是阐明AD分子机制的强大工具.
- 这些发现突出显示了阿尔茨海默病的显著代谢失调,涉及氨基酸,脂质,碳水化合物,核酸和辅因子/维生素代谢.
- 代谢变化与APOE ε4等遗传因素之间的相互作用为AD病变的发病提供了关键的见解.
关键词:
阿尔茨海默氏症的疾病是阿尔茨海默氏症.氨基酸代谢 氨基酸代谢碳水化合物代谢的代谢高分辨率的新陈代谢学脂质新陈代谢 脂质新陈代谢同因子和维生素的新陈代谢.神经病理学神经病理学核酸代谢的核酸代谢没有目标的代谢学.更多相关视频
10:46Using Enzyme-based Biosensors to Measure Tonic and Phasic Glutamate in Alzheimer's Mouse Models
Published on: May 3, 2017
11.7K
06:41Quantitative Analysis of Mitochondria-Associated Endoplasmic Reticulum Membrane (MAM) Stabilization in a Neural Model of Alzheimer's Disease (AD)
Published on: January 10, 2025
1.2K
相关概念视频
01:26Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
01:22Alzheimer's Disease: Treatment
827
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
827